Benchmark reiterates Hold stock rating on Bio-Techne after Q4 results

Investing.com reports that Benchmark has maintained a Hold rating for Bio-Techne Corp. (NASDAQ:TECH) after the company's fourth-quarter fiscal 2026 results were released. Bio-Techne disclosed revenues of $321.2 million for the quarter, showing a 1% year-over-year increase. Earnings came in at $0.52 per share, matching the adjusted EPS forecast.

The stock is currently trading at $72.51, close to its 52-week high of $72.62, with a 23% increase year-to-date. According to InvestingPro analysis, the stock appears overvalued compared to its Fair Value estimate, despite past strong returns. The Diagnostics segment experienced 8% organic growth, while Protein Sciences grew organically by 1%.

However, Diagnostics revenues fell by 8% due to the sale of a product line last year. Benchmark had predicted revenues of $314.0 million, with adjusted EPS of $0.53. Bio-Techne has not held an earnings conference call or provided forward financial guidance and is expected to be acquired by Merck KGaA sometime later this year or early next year.